Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, has begun shipping an authorized generic version of Merck’s INVANZ^® (ertapenem for injection).  Endo’s subsidiary, Endo Ventures Limited, recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., Inc., of Kenilworth, N.J. allowing Par to launch and distribute an authorized generic of the product. 

According to IQVIA data, U.S. sales of INVANZ^® were approximately $390 million for the 12 months ending May 31, 2018.

INVANZ^® is a registered trademark of Merck Sharp & Dohme Corp.

About Endo International plc

Endo International plc is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.

About Par Pharmaceutical 

Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a research and development pipeline of approximately 200 potential new products.  Par is an operating company of Endo International plc.